Physician profile
Calvin D Lyons
NPI 1811149404
$6,052.82
in general payments reported to CMS, 2019-2025
36 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $550 · 2021: $1,140 · 2022: $663 · 2023: $2,125 · 2024: $338 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $1,000 · Travel and Lodging: $838 · Gift: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.32 |
| Education | $1,000.00 |
| Travel and Lodging | $837.89 |
| Gift | $245.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,034.63 | 2020-2024 | Davinci Xi, Da Vinci Surgical System |
| Medtronic, INC. | $664.74 | 2021-2024 | Signia |
| Braintree Laboratories, INC. | $410.21 | 2019-2025 | Suflave, Sutab |
| Covidien LP | $325.00 | 2020 | |
| Merck Sharp & Dohme LLC | $318.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $304.65 | 2020-2024 | Gattex |
| Abbvie INC. | $244.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $200.92 | 2021-2022 | |
| Acera Surgical, INC. | $193.29 | 2023-2025 | Restrata Wound Matrix |
| Foundation Medicine, INC. | $148.30 | 2021 | |
| Smith+Nephew, INC. | $130.50 | 2022 | |
| Lundbeck LLC | $120.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.01 | 2019 | |
| Welch Allyn | $79.69 | 2021 | |
| Baxter Healthcare | $79.69 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $72.45 | 2025 | Provenge |
| Coloplast Corp | $59.51 | 2023-2024 | Sensura Mio |
| Pacira Pharmaceuticals Incorporated | $50.18 | 2019-2021 | |
| Janssen Biotech, INC. | $48.81 | 2025 | Erleada |
| Conmed Corporation | $43.75 | 2022 | |
| Sumitomo Pharma America, INC. | $35.84 | 2025 | Gemtesa |
| Calyxo, INC. | $34.52 | 2025 | Cvac Aspiration System |
| La Jolla Pharmaceutical Company | $34.37 | 2020 | |
| Ferring Pharmaceuticals INC. | $33.57 | 2024-2025 | Rebyota |
| Sanara Medtech INC. | $30.56 | 2024 | Celleraterx |
| Vioptix INC | $30.04 | 2021 | |
| Antares Pharma, INC. | $29.60 | 2025 | Xyosted |
| Innovation Technologies INC | $26.92 | 2024 | Irrisept |
| Kci USA, INC. | $26.24 | 2020 | |
| Endo USA, INC. | $25.08 | 2025 | Aveed, Xiaflex |
| Urogen Pharma, INC. | $23.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.50 | 2025 | |
| Teleflex LLC | $22.27 | 2025 | Barrigel |
| 180 Medical, INC. | $21.31 | 2025 | |
| Olympus America INC. | $14.38 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.